Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.
Press releases
March 11, 2024
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
February 24, 2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
Contact our media team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
For any other request, please call the switchboard: +33 1 53 77 40 00
Publications
Declaration of extra-financial performance 2023 (ESG Report)
Half Year 2023 Financial Report XBRL Package
Half Year 2023 Financial Report
First quarter 2023 results